Electronic Letters to:

Endocrine Care: Joakim Hennings, Örjan Lindhe, Mats Bergström, Bengt Långström, Anders Sundin, and Per Hellman [11C]Metomidate Positron Emission Tomography of Adrenocortical Tumors in Correlation with Histopathological Findings J Clin Endocrinol Metab 2006; 91: 1410-1414 [Abstract] [Full text] [PDF]

eLetters: Submit a response to this article

Electronic letters published:

[¹⁸F]FETO - a longer lived PET tracer for the measurement of 11-beta-hydroxylase activity

Markus Mitterhauser, Wolfgang Wadsak   (8 September 2006)

[18F]FETO - a longer lived PET tracer for the measurement of 11-beta-hydroxylase activity 8 September 2006
Markus Mitterhauser, Head of Radiopharmacy Department of Nuclear Medicine, Medical University of Vienna, Wolfgang Wadsak Send letter to journal: Re: [18F]FETO - a longer lived PET tracer for the measurement of 11-beta-hydroxylase activity markus.mitterhauser{at}meduniwien.ac.at Markus Mitterhauser, et al.	We read with interest the recent article concerning adrenocortical imaging with the positron-emitter [11C]Metomidate (MTO) by Hennings et al. (1). The authors prove the significant impact of 11-beta-hydroxylase imaging for the diagnosis and staging of adrenocortical disorders. The authors conclude: "To make MTO-PET more available, an MTO analog labeled with a more long-lived positron emitter than 11C has been developed." In fact, our group was working on this challenge for the last few years and we were able to develop an F-18 labeled analogue, [18F]FETO. This novel PET tracer could allow PET centres to integrate specific adrenocortical imaging - using selective 11-beta hydroxylase inhibitors - into their clinical routine even if they do not have an on-site radiopharmaceutical production unit at their disposal. Articles describing the radiosynthesis (2), preclinical evaluation in rats (3), first pilot study in healthy human volunteers (4) and metabolic properties (5) of [18F]FETO have already been published. References 1. Hennings J, Lindhe Ö, Bergström M, Långström B, Sundin A, Hellman P. 2006. [11C]Metomidate Positron Emission Tomography of Adrenocortical Tumors in Correlation with Histopathological Findings. J Clin Endocrinol Metab 91:1410-1414. 2. Wadsak W and Mitterhauser M. 2003. Synthesis of [18F]FETO, a novel potential 11-beta hydroxylase inhibitor. J Label Compd Radpharm 46:379- 388. 3. Mitterhauser M, Wadsak W, Wabnegger L, Sieghart W, Viernstein H, Kletter K, Dudczak R. 2003. In vivo and in vitro evaluation of [18F]FETO with respect to the adrenocortical and GABAergic system in rats. Eur J Nucl Med Mol Imaging 30:1398-1401. 4. Wadsak W, Mitterhauser M, Rendl G, Schuetz M, Mien L-K, Dudczak R, Kletter K, Karanikas G. 2006. [18F]FETO for adrenocortical PET imaging: a pilot study in healthy volunteers. Eur J Nucl Med Mol Imaging 33:669-672. 5. Ettlinger DE, Wadsak W, Mien L-K, Machek M, Wabnegger L, Rendl G, Karanikas G, Viernstein H, Kletter K, Dudczak R, Mitterhauser M. 2006. The metabolic profile of [18F]FETO. Eur J Nucl Med Mol Imaging 33:928-931.